Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable.

Eisinger RW, Dieffenbach CW, Fauci AS.

JAMA. 2019 Feb 5;321(5):451-452. doi: 10.1001/jama.2018.21167. No abstract available.

PMID:
30629090
2.

Ending the HIV Epidemic in the United States: Closing the Implementation Gaps.

Marston HD, Dieffenbach CW, Fauci AS.

Ann Intern Med. 2018 Sep 18;169(6):411-412. doi: 10.7326/M18-1944. Epub 2018 Aug 21. No abstract available.

PMID:
30140920
3.

Immunology. Immune activation with HIV vaccines.

Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP.

Science. 2014 Apr 4;344(6179):49-51. doi: 10.1126/science.1250672. No abstract available.

4.

HIV-AIDS: much accomplished, much to do.

Fauci AS, Folkers GK, Dieffenbach CW.

Nat Immunol. 2013 Nov;14(11):1104-7. doi: 10.1038/ni.2735.

PMID:
24145780
5.

Preventing HIV transmission through antiretroviral treatment-mediated virologic suppression: aspects of an emerging scientific agenda.

Dieffenbach CW.

Curr Opin HIV AIDS. 2012 Mar;7(2):106-10. doi: 10.1097/COH.0b013e32834f3f13. Review.

PMID:
22227584
6.

Thirty years of HIV and AIDS: future challenges and opportunities.

Dieffenbach CW, Fauci AS.

Ann Intern Med. 2011 Jun 7;154(11):766-71. doi: 10.7326/0003-4819-154-11-201106070-00345. Epub 2011 May 31.

PMID:
21628350
7.

A way forward: the National HIV/AIDS Strategy and reducing HIV incidence in the United States.

Millett GA, Crowley JS, Koh H, Valdiserri RO, Frieden T, Dieffenbach CW, Fenton KA, Benjamin R, Whitescarver J, Mermin J, Parham-Hopson D, Fauci AS.

J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 2:S144-7. doi: 10.1097/QAI.0b013e3181fbcb04.

PMID:
21406986
8.

Rethinking prevention of HIV type 1 infection.

Burns DN, Dieffenbach CW, Vermund SH.

Clin Infect Dis. 2010 Sep 15;51(6):725-31. doi: 10.1086/655889. Review. Erratum in: Clin Infect Dis. 2010 Oct 15;51(8):995.

9.

Fighting HIV/AIDS in Washington, D.C.

Greenberg AE, Hader SL, Masur H, Young AT, Skillicorn J, Dieffenbach CW.

Health Aff (Millwood). 2009 Nov-Dec;28(6):1677-87. doi: 10.1377/hlthaff.28.6.1677.

PMID:
19887408
10.

HIV vaccine development: Lessons from the past, informing the future.

Bradac J, Dieffenbach CW.

IDrugs. 2009 Jul;12(7):435-9. Review.

PMID:
19579164
11.

Universal voluntary testing and treatment for prevention of HIV transmission.

Dieffenbach CW, Fauci AS.

JAMA. 2009 Jun 10;301(22):2380-2. doi: 10.1001/jama.2009.828. No abstract available.

PMID:
19509386
12.

Cataloguing the HIV type 1 human protein interaction network.

Ptak RG, Fu W, Sanders-Beer BE, Dickerson JE, Pinney JW, Robertson DL, Rozanov MN, Katz KS, Maglott DR, Pruitt KD, Dieffenbach CW.

AIDS Res Hum Retroviruses. 2008 Dec;24(12):1497-502. doi: 10.1089/aid.2008.0113. Review.

13.

HIV vaccine research: the way forward.

Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC.

Science. 2008 Jul 25;321(5888):530-2. doi: 10.1126/science.1161000.

PMID:
18653883
14.

Defining and solving the essential protein-protein interactions in HIV infection.

Finzi D, Dieffenbach CW, Basavappa R.

J Struct Biol. 2007 May;158(2):148-55. Epub 2006 Nov 9. Review.

PMID:
17175170
15.

Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis.

Finzi D, Plaeger SF, Dieffenbach CW.

Clin Vaccine Immunol. 2006 Jul;13(7):715-21. Review. No abstract available.

16.

General concepts for PCR primer design.

Dieffenbach CW, Lowe TM, Dveksler GS.

PCR Methods Appl. 1993 Dec;3(3):S30-7. No abstract available.

17.

Induction of IFN-gamma in macrophages by lipopolysaccharide.

Fultz MJ, Barber SA, Dieffenbach CW, Vogel SN.

Int Immunol. 1993 Nov;5(11):1383-92.

PMID:
8260452
18.

Setting up a PCR laboratory.

Dieffenbach CW, Dveksler GS.

PCR Methods Appl. 1993 Oct;3(2):S2-7. No abstract available.

19.
20.

Mouse hepatitis virus strain A59 and blocking antireceptor monoclonal antibody bind to the N-terminal domain of cellular receptor.

Dveksler GS, Pensiero MN, Dieffenbach CW, Cardellichio CB, Basile AA, Elia PE, Holmes KV.

Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1716-20.

21.

Several members of the mouse carcinoembryonic antigen-related glycoprotein family are functional receptors for the coronavirus mouse hepatitis virus-A59.

Dveksler GS, Dieffenbach CW, Cardellichio CB, McCuaig K, Pensiero MN, Jiang GS, Beauchemin N, Holmes KV.

J Virol. 1993 Jan;67(1):1-8.

22.

Expression of MHV-A59 receptor glycoproteins in susceptible and resistant strains of mice.

Dveksler GS, Basile AA, Cardellichio CB, Beauchemin N, Dieffenbach CW, Holmes KV.

Adv Exp Med Biol. 1993;342:267-72. No abstract available.

PMID:
8209741
23.

Hantaan virus infection of human endothelial cells.

Pensiero MN, Sharefkin JB, Dieffenbach CW, Hay J.

J Virol. 1992 Oct;66(10):5929-36.

24.
25.

Cloning and expression of human erythropoietin, a paradigm.

Dieffenbach CW.

J Vasc Surg. 1992 May;15(5):909-11. No abstract available.

PMID:
1578562
26.

Analysis of gene expression: use of oligonucleotide primers for glyceraldehyde-3-phosphate dehydrogenase.

Dveksler GS, Basile AA, Dieffenbach CW.

PCR Methods Appl. 1992 May;1(4):283-5. No abstract available.

27.

Effect of different laboratory techniques for guanidinium-phenol-chloroform RNA extraction on A260/A280 and on accuracy of mRNA quantitation by reverse transcriptase-PCR.

Yamaguchi M, Dieffenbach CW, Connolly R, Cruess DF, Baur W, Sharefkin JB.

PCR Methods Appl. 1992 May;1(4):286-90. No abstract available.

28.

Cloning of the mouse hepatitis virus (MHV) receptor: expression in human and hamster cell lines confers susceptibility to MHV.

Dveksler GS, Pensiero MN, Cardellichio CB, Williams RK, Jiang GS, Holmes KV, Dieffenbach CW.

J Virol. 1991 Dec;65(12):6881-91.

29.

Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody.

Svetić A, Finkelman FD, Jian YC, Dieffenbach CW, Scott DE, McCarthy KF, Steinberg AD, Gause WC.

J Immunol. 1991 Oct 1;147(7):2391-7.

PMID:
1717559
30.
31.

Fluid flow decreases preproendothelin mRNA levels and suppresses endothelin-1 peptide release in cultured human endothelial cells.

Sharefkin JB, Diamond SL, Eskin SG, McIntire LV, Dieffenbach CW.

J Vasc Surg. 1991 Jul;14(1):1-9.

PMID:
2061949
32.

Detection of toxic viral-associated double-stranded RNA (dsRNA) in influenza-infected lung.

Majde JA, Brown RK, Jones MW, Dieffenbach CW, Maitra N, Krueger JM, Cady AB, Smitka CW, Maassab HF.

Microb Pathog. 1991 Feb;10(2):105-15.

PMID:
1890949
33.

2',5'-Oligoadenylate synthetase gene expression in revertants of ras-transformed NIH3T3 fibroblasts.

Rimoldi D, Dieffenbach CW, Friedman RM, Samid D.

Exp Cell Res. 1990 Nov;191(1):76-82.

PMID:
1699771
34.

Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction.

Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, Orenstein JM, Dieffenbach CW, Friedman RM, Meltzer MS.

J Immunol. 1990 Oct 15;145(8):2669-76.

PMID:
1976701
35.

Induction of interferon-beta and 2',5'-oligoadenylate synthetase mRNAs by interleukin 6 during differentiation of murine myeloid cells.

Bickel M, Dveksler G, Dieffenbach CW, Ruhl S, Midura SB, Pluznik DH.

Cytokine. 1990 Jul;2(4):238-46. Erratum in: Cytokine. 1990 Nov;2(6):473.

PMID:
2151766
36.

A computer program for selection of oligonucleotide primers for polymerase chain reactions.

Lowe T, Sharefkin J, Yang SQ, Dieffenbach CW.

Nucleic Acids Res. 1990 Apr 11;18(7):1757-61.

37.

Cloning of murine gelsolin and its regulation during differentiation of embryonal carcinoma cells.

Dieffenbach CW, SenGupta DN, Krause D, Sawzak D, Silverman RH.

J Biol Chem. 1989 Aug 5;264(22):13281-8.

38.

Beta interferon subtype 1 induction by tumor necrosis factor.

Jacobsen H, Mestan J, Mittnacht S, Dieffenbach CW.

Mol Cell Biol. 1989 Jul;9(7):3037-42.

39.

Purification and analysis of murine 2-5A-dependent RNase.

Silverman RH, Jung DD, Nolan-Sorden NL, Dieffenbach CW, Kedar VP, SenGupta DN.

J Biol Chem. 1988 May 25;263(15):7336-41.

40.

Independent regulation of ppp(A2'p)nA-dependent RNase in NIH 3T3, clone 1 cells by growth arrest and interferon treatment.

Krause D, Panet A, Arad G, Dieffenbach CW, Silverman RH.

J Biol Chem. 1985 Aug 5;260(16):9501-7.

41.

Regulation of ppp(A2'p)nA-dependent RNase levels during interferon treatment and cell differentiation.

Krause D, Silverman RH, Jacobsen H, Leisy SA, Dieffenbach CW, Friedman RM.

Eur J Biochem. 1985 Feb 1;146(3):611-8.

42.

Polyclonal antibody directed against 2-5A-dependent RNase.

Dieffenbach CW, Krause D, Silverman RH.

Prog Clin Biol Res. 1985;202:105-14. No abstract available.

PMID:
2421296
43.

Structural requirements of (2'-5') oligoadenylate for protein synthesis inhibition in human fibroblasts.

Drocourt JL, Dieffenbach CW, Ts'o PO, Justesen J, Thang MN.

Nucleic Acids Res. 1982 Mar 25;10(6):2163-74.

44.

Translation of exogenous interferon mRNA in intact mammalian cells.

Greene JJ, Dieffenbach CW, Ts'o PO.

Methods Enzymol. 1981;79(Pt B):104-11. No abstract available.

PMID:
6173655
45.

Species-specific posttranscriptional regulation of interferon synthesis.

Greene JJ, Dieffenbach CW, Yang LC, Ts'o PO.

Biochemistry. 1980 May 27;19(11):2485-91.

PMID:
6155939
46.

Inactivation of interferon mRNA in the shutoff of human interferon synthesis.

Greene JJ, Dieffenbach CW, Ts'o PO.

Nature. 1978 Jan 5;271(5640):81-3. No abstract available.

PMID:
625329

Supplemental Content

Loading ...
Support Center